MA54009B1 - Formulation d'afabicine et son procédé de préparation - Google Patents

Formulation d'afabicine et son procédé de préparation

Info

Publication number
MA54009B1
MA54009B1 MA54009A MA54009A MA54009B1 MA 54009 B1 MA54009 B1 MA 54009B1 MA 54009 A MA54009 A MA 54009A MA 54009 A MA54009 A MA 54009A MA 54009 B1 MA54009 B1 MA 54009B1
Authority
MA
Morocco
Prior art keywords
afabicin
formulation
preparation
compositions
present
Prior art date
Application number
MA54009A
Other languages
English (en)
Other versions
MA54009A1 (fr
Inventor
Marie Decrette
Aude Anne-Laure Colin
Sebastien Chabaud
Original Assignee
Debiopharm Int Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Int Sa filed Critical Debiopharm Int Sa
Publication of MA54009A1 publication Critical patent/MA54009A1/fr
Publication of MA54009B1 publication Critical patent/MA54009B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques solides contenant de l'afabicine présentant des caractéristiques supérieures de dissolution. Cet effet bénéfique est accompli par la présence d'un composé histidine pour la fabrication des compositions. La présente invention concerne en outre des procédés de préparation de telles compositions et des utilisations associées.
MA54009A 2019-02-14 2020-02-14 Formulation d'afabicine et son procédé de préparation MA54009B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157255 2019-02-14
PCT/EP2020/053882 WO2020165407A1 (fr) 2019-02-14 2020-02-14 Formulation d'afabicine et son procédé de préparation

Publications (2)

Publication Number Publication Date
MA54009A1 MA54009A1 (fr) 2022-05-31
MA54009B1 true MA54009B1 (fr) 2022-10-31

Family

ID=65440901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA54009A MA54009B1 (fr) 2019-02-14 2020-02-14 Formulation d'afabicine et son procédé de préparation

Country Status (28)

Country Link
US (1) US20220142993A1 (fr)
EP (1) EP3923914B1 (fr)
JP (1) JP7383715B2 (fr)
KR (1) KR20210127187A (fr)
CN (2) CN116327781A (fr)
AU (1) AU2020223515A1 (fr)
BR (1) BR112021015825B1 (fr)
CA (1) CA3129508A1 (fr)
CL (1) CL2021002149A1 (fr)
CY (1) CY1126077T1 (fr)
DK (1) DK3923914T3 (fr)
EA (1) EA202192246A1 (fr)
ES (1) ES2944535T3 (fr)
FI (1) FI3923914T3 (fr)
HR (1) HRP20230437T1 (fr)
HU (1) HUE062061T2 (fr)
IL (1) IL285204A (fr)
LT (1) LT3923914T (fr)
MA (1) MA54009B1 (fr)
MX (1) MX2021009799A (fr)
PL (1) PL3923914T3 (fr)
PT (1) PT3923914T (fr)
RS (1) RS64158B1 (fr)
SG (1) SG11202108591PA (fr)
SI (1) SI3923914T1 (fr)
TN (1) TN2021000159A1 (fr)
UA (1) UA128316C2 (fr)
WO (1) WO2020165407A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007219A (es) 2018-12-21 2021-09-23 Acurx Pharmaceuticals Llc Inhibidores de la adn polimerasa iiic y sus usos.
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002367773A1 (en) 2001-04-06 2003-11-03 Affinium Pharmaceuticals, Inc. Fab i inhibitors
CN101415701A (zh) * 2005-12-05 2009-04-22 Affinium医药公司 作为fabi抑制剂的杂环丙烯酰胺化合物和抗菌剂
EP2125802A4 (fr) * 2007-02-16 2014-08-20 Debiopharm Int Sa Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
RS58898B1 (sr) 2012-06-19 2019-08-30 Debiopharm Int Sa Prolek derivati (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)akrilamida
LT3419628T (lt) 2016-02-26 2021-01-25 Debiopharm International Sa Medikamentas diabetinėms pėdų infekcijoms gydyti

Also Published As

Publication number Publication date
SG11202108591PA (en) 2021-09-29
BR112021015825A2 (pt) 2021-10-13
WO2020165407A1 (fr) 2020-08-20
EP3923914B1 (fr) 2023-04-12
MA54009A1 (fr) 2022-05-31
CN116327781A (zh) 2023-06-27
UA128316C2 (uk) 2024-06-05
AU2020223515A1 (en) 2021-08-19
SI3923914T1 (sl) 2023-08-31
CN113423390B (zh) 2023-05-23
US20220142993A1 (en) 2022-05-12
JP7383715B2 (ja) 2023-11-20
TN2021000159A1 (en) 2023-04-04
CL2021002149A1 (es) 2022-03-04
CY1126077T1 (el) 2023-11-15
DK3923914T3 (da) 2023-05-01
RS64158B1 (sr) 2023-05-31
PL3923914T3 (pl) 2023-08-07
CN113423390A (zh) 2021-09-21
HRP20230437T1 (hr) 2023-07-07
CA3129508A1 (fr) 2020-08-20
BR112021015825B1 (pt) 2024-03-12
FI3923914T3 (fi) 2023-04-27
HUE062061T2 (hu) 2023-09-28
EP3923914A1 (fr) 2021-12-22
KR20210127187A (ko) 2021-10-21
MX2021009799A (es) 2021-09-08
ES2944535T3 (es) 2023-06-22
IL285204A (en) 2021-09-30
LT3923914T (lt) 2023-07-25
PT3923914T (pt) 2023-05-04
EA202192246A1 (ru) 2021-11-18
JP2022520170A (ja) 2022-03-29

Similar Documents

Publication Publication Date Title
MA54009B1 (fr) Formulation d'afabicine et son procédé de préparation
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
FR2525205A1 (fr) Composition biocide a base d'isothiazolone et de glutaraldehyde et procede pour le traitement d'eau de refroidissement ou d'eau utilisee dans la fabrication du papier
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
FR3086943B1 (fr) Copolymere d'ethylene et de beta-farnesene
MA31684B1 (fr) Composition pharmaceutique contenant un antagoniste des canaux calciques de type dihydropyridine et son procédé de préparation
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
MA53189B2 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
MA29950B1 (fr) Nouveau derive de la pleuromutiline et son utilisation
MA57000B1 (fr) Dérivés d'alpha-d-galactopyranoside
FR3100723B1 (fr) Procédé de préparation d’atomes métalliques isolés ou d’un mélange d’atomes métalliques isolés et de nanoparticules métalliques sur matériau carboné
MA51664B1 (fr) Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide
CA2473203A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
FR3105788B1 (fr) Procede de preparation de particules enrobees d’oxyde de silicium par pyrolyse par projection de flamme
FR3105787B1 (fr) Procede de preparation de particules d’oxyde de zinc enrobees par pyrolyse par projection de flamme
FR2401132A1 (fr) Nouveaux derives de triphenylbutene-1, leur procede de production et composition pharmaceutique les contenant
HUP0401405A2 (hu) Xa faktor inhibitor tulajdonságú fenilszármazékok és ezeket tartalmazó gyógyszerkészítmények
FR3105976B1 (fr) Composition de matière et procédé de préparation de celle-ci
KR950003282A (ko) 살균성 스피로헤테로시클릭 화합물 및 이들의 제조방법
CA3156074A1 (fr) Inhibiteurs de mll1 et agents anticancereux
US2614918A (en) Method of setting fruit and composition therefor
US2411443A (en) Manufacture of soap
FR2403798A1 (fr) Compositions synergiques a base de disulfure de bis(2-pyridyl-1-oxyde et leur utilisation pour leur activite anti-inflammatoire